Breaking News, Trials & Filings

VBI Vaccines Announces Positive Study Results

From the randomized, placebo-controlled Phase 1 study of VBI-1501, the company’s CMV vaccine candidate

VBI Vaccines announced positive final top-line results from the randomized, placebo-controlled Phase 1 study of VBI-1501, the company’s prophylactic cytomegalovirus (CMV) vaccine candidate.    VBI-1501 was developed using the company’s proprietary enveloped virus-like particle (eVLP) technology and presents a modified form of the glycoprotein B (gB) found on CMV. The final Phase 1 study results demonstrated that VBI-1501 was safe and well-tolerated at all doses. The highest dose of VBI-1...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters